• 제목/요약/키워드: psychiatric disorder

검색결과 528건 처리시간 0.029초

신경아교세포와 기분장애 (Neuroglia and Mood Disorder)

  • 이정구;서미경;박성우;김영훈
    • 생물정신의학
    • /
    • 제22권2호
    • /
    • pp.34-39
    • /
    • 2015
  • Mood disorder is a common psychiatric illness with a high lifetime prevalence in the general population. A serious problem such as suicide is commonly occurring in the patients with depression. Till now, the monoamine hypothesis has been the most popular theory of pathogenesis for depression. However, the more specific pathophysiology of depression and cellular molecular mechanism underlying action of commercial antidepressants have not been clearly defined. Several recent studies demonstrated that glial cells, especially astrocytes, are a promising answer to the pathophysiology of depression. In this article, current understanding of biology and molecular mechanisms of glial cells in the pathology of mood disorder and new research on the pathophysiology of depression will be discussed.

수면 관련 식이 장애 (Sleep-Related Eating Disorder)

  • 박영민
    • 수면정신생리
    • /
    • 제18권1호
    • /
    • pp.5-9
    • /
    • 2011
  • Sleep-related eating disorder (SRED) is a newly recognized parasomnia that describes a clinical condition of compulsive eating under an altered level of consciousness during sleep. Recently, it is increasingly recognized in clinical practice. The exact etiology of SRED is unclear, but it is assumed that SRED might share features of both sleepwalking and eating disorder. There have been also accumulating reports of SRED related to the administration of various psychotropic drugs, such as zolpidem, triazolam, olanzapine, and combinations of psychotropics. Especially, zolpidem in patients with underlying sleep disorders that cause frequent arousals, may cause or augment sleep related eating behavior. A thorough sleep history is essential to recognition and diagnosis of SRED. The timing, frequency, and description of food ingested during eating episodes should be elicited, and a history of concurrent psychiatric, medical, sleep disorders must also be sought and evaluated. Interestingly, dopaminergic agents as monotherapy were effective in some trials. Success with combinations of dopaminergic and opioid drugs, with the addition of sedatives, has also been reported in some case reports.

BDNF가 ADHD의 병인과 치료에 미치는 영향 (Association between the Brain-Derived Neurotropic Factor and Attention Deficit Hyperactivity Disorder)

  • 강나리;송재민;곽영숙
    • 생물정신의학
    • /
    • 제25권2호
    • /
    • pp.21-30
    • /
    • 2018
  • Attention deficit hyperactivity disorder (ADHD) is a common childhood psychiatric disorder. Recently, it has been suggested that brain-derived neurotropic factor (BDNF) may play a role in the pathogenesis of ADHD. Our aim of this review is to understand the physiological functions of BDNF and its potential relationship with ADHD and therapeutic approaches of ADHD. Searches were conducted in Pubmed and Research Information Service System (RISS). In this review, we summarized important literatures for the physiological functions of BDNF in neurodevelopment, change of serum BDNF level in ADHD, association of BDNF polymorphism and ADHD and potential association of treatment of ADHD with serum BDNF level. Further studies are required to more clearly understand the source and the role of BDNF in ADHD and to develop BDNF based-ADHD treatement.

  • PDF

주요우울증을 동반한 고도비만 환자에 대한 행동요법을 병행한 리라글루티드 치료의 2예 (Two Cases of Obesity Treatment Using Liraglutide 3 mg with Intensive Behavioral Changes in Morbidly Obese Patients with Major Depressive Disorder)

  • 고혜진
    • 비만대사연구학술지
    • /
    • 제1권1호
    • /
    • pp.39-42
    • /
    • 2022
  • Obesity is a chronic disease associated with severe complications. A major complication of obesity is depression, which can worsen obesity and vice versa. In addition, most antidepressants or antipsychotics cause weight gain, and the relationship between obesity and depression is clinically critical. However, treatment of obese patients with major depressive disorder is complicated. Bariatric physicians should provide appropriate behavioral interventions alongside pharmacological treatment, considering psychiatric symptoms, drug side effects, and drug interactions. Two successful cases of moderate-to-severe obese patients with major depressive disorder who had been treated for obesity using behavioral intervention therapy along with liraglutide will be discussed. This report highlights the safety and efficacy of liraglutide treatment of obesity in patients with depression who take antidepressants and antipsychotics.

사회불안장애와 공황장애에 동반된 우울증상의 특성 비교 (Comparison of Depressive Symptoms between Social Anxiety Disorder and Panic Disorder)

  • 김선영;임세원;신영철;신동원;오강섭
    • 생물정신의학
    • /
    • 제22권4호
    • /
    • pp.216-222
    • /
    • 2015
  • Objectives The principal aim of the present study was to investigate the characteristic depressive symptoms in patients with social anxiety disorder (SAD) and panic disorder in comparison to patients with depressive disorder. Methods This study included 132 patients with SAD, 128 panic disorder and 64 depressive disorder (major depressive disorder, dysthymia etc.) patients without comorbid psychiatric disorders. The Beck Depressive Inventory (BDI) is used to measure depressive symptoms. We divided BDI into three categories originally described by Shafer AB, including negative attitude toward self, performance impairment, and somatic symptoms. We compared the depressive symptoms of SAD, panic disorder and depressive disorder by using ANOVA. Results Negative attitude toward self was noticeable in SAD (SAD $0.54{\pm}0.23$, panic disorder $0.41{\pm}0.17$, depressive disorder $0.46{\pm}0.11$, p < 0.001). Performance impairment and somatic symptoms were remarkable in panic disorder than in SAD and depressive disorder (performance impairment : SAD $0.39{\pm}0.21$, panic disorder $0.44{\pm}0.14$, depressive disorder $0.40{\pm}0.09$, p = 0.009 ; somatic symptoms : SAD $0.07{\pm}0.10$, panic disorder $0.15{\pm}0.12$, depressive disorder $0.14{\pm}0.08$, p < 0.001). Conclusions The results facilitate an approach to optimal treatment for patients with comorbidity of anxiety disorder and depression.

Childhood Onset of Anti-N-Methyl-D-Aspartate Receptor Encephalitis Without Teratoma Masquerading as a Psychotic Disorder

  • Yeum, Tae-Sung;Lee, Jung;Park, Sung-Yeol;Joen, Yaelim;Kim, Bung-Nyun
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제30권3호
    • /
    • pp.127-131
    • /
    • 2019
  • Many neurologic disorders manifest as psychiatric symptoms. Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is an autoimmune disease of the brain characterized by numerous neurological and psychiatric features. Despite being rare, its prevalence is rapidly increasing and early management is critical in ensuring successful and sustainable recovery. Therefore, the illness should be considered as a differential diagnosis when clinically assessing patients. This report presents a case of a female child who was hospitalized for acute psychiatric manifestations, which was later confirmed as anti-NMDA receptor encephalitis. She recovered relatively successfully after combined neurological and psychiatric treatment. This report provides information on the clinical course of early onset anti-NMDA receptor encephalitis, including treatment strategy and prognosis.

불안장애의 치료추구시간에 대한 공존 정신질환의 영향 : 사회불안장애와 공황장애 간 비교 (Influence of Comorbid Mental Disorder on Time to Seeking Treatment in Anxiety Disorder : Comparison of Social Anxiety Disorder and Panic Disorder)

  • 김혜민;하주원;임세원;오강섭
    • 대한불안의학회지
    • /
    • 제8권2호
    • /
    • pp.146-152
    • /
    • 2012
  • Objective : Individuals with anxiety disorders experience a wide range of time to seeking treatment (TST) as well as various comorbid mental disorders. The present study examined the TST in social anxiety disorder (SAD) and panic disorder. This study aimed to find out the influence of comorbid mental disorder on TST of anxiety disorder through the comparison of SAD and panic disorder. Methods : This study included 311 SAD and 378 panic disorder patients at the initial visit of psychiatric clinic. Contribution of clinical (number of comorbidity, comorbid type and onset age) and demographic (current age) factors to TST were investigated by multivariate analysis. Results : The median length of TST was 14.03 years in SAD and 2.26 years in panic disorder. In social anxiety disorder, fewer comorbidity, younger onset age, and older age were factors associated with delayed TST. In panic disorder, only younger onset age was associated with delayed TST. In both disorders, comorbid depressive disorder was associated with shorter TST. Conclusion : Our data provided the differences in illness behavior needing help based on comorbid mental disorders between SAD and panic disorder. In addition to comorbid disorder, factors affecting TST of anxiety disorder requires future investigation.

Neurofeedback의 이해와 임상적용 (The Introduction and Clinical Applications of Nuerofeedback)

  • 박형배;성형모
    • 정신신체의학
    • /
    • 제14권1호
    • /
    • pp.8-17
    • /
    • 2006
  • 뉴로피드백(neurofeedback)은 EEG biofeedback, neurotherapy 등의 이름으로 불리기도 하는 새로운 치료법으로, 뇌파를 이용하고 뇌(brain) 자체와 뇌 기능(brain function)을 대상으로 한다는 점에서는 일반적인 바이오피드백(biofeedback)과는 차이가 있다. 따라서 바이오피드백의 한 형태로 출발을 하였지만, 현재는 독자적이고 전문화된 방식의 새로운 치료법으로 자리 메김을 하고 있다. 뉴로피드백에 대한 이해를 도우기 위해 뉴로피드백의 역사와 이론적 배경을 우선 알아본 후, 실제 임상에서 어떻게 사용되고 있는 지를 알아보고자 한다. 뉴로피드백은 임상분야에서 간질(epilepsy)의 치료에 처음으로 도입된 이후 그 효과가 입증되었으며, 주의력결핍과잉행동장애(attention deficit hyperactivity disorder, ADHD), 불안 및 우울장애, 수면장애, 물질의존 등의 많은 정신과 질환에 효과적으로 사용되고 있다. 정신과 질환이외에도 두통, 만성통증, 만성피로증후군 등 많은 다양한 영역에 걸쳐 적용되고 있다. 최근에는 질환들 뿐 만이 아니라, 스포츠와 예술 활동에서의 수행능력(peak performance)의 향상, 인지기능의 향상 등의 분야로 활용범위가 확대되고 있어 뉴로피드백의 효용성과 그 가능성에 대한 기대가 더욱 높아지고 있다.

  • PDF

Berberine alleviates symptoms of anxiety by enhancing dopamine expression in rats with post-traumatic stress disorder

  • Lee, Bombi;Shim, Insop;Lee, Hyejung;Hahm, Dae-Hyun
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제22권2호
    • /
    • pp.183-192
    • /
    • 2018
  • Post-traumatic stress disorder (PTSD) is a trauma-induced psychiatric disorder characterized by impaired fear extermination, hyperarousal, anxiety, depression, and amnesic symptoms that may involve the release of monoamines in the fear circuit. The present study measured several anxiety-related behavioral responses to examine the effects of berberine (BER) on symptoms of anxiety in rats after single prolonged stress (SPS) exposure, and to determine if BER reversed the dopamine (DA) dysfunction. Rats received BER (10, 20, or 30 mg/kg, intraperitoneally, once daily) for 14 days after SPS exposure. BER administration significantly increased the time spent in the open arms and reduced grooming behavior during the elevated plus maze test, and increased the time spent in the central zone and the number of central zone crossings in the open field test. BER restored neurochemical abnormalities and the SPS-induced decrease in DA tissue levels in the hippocampus and striatum. The increased DA concentration during BER treatment may partly be attributed to mRNA expression of tyrosine hydroxylase and the DA transporter in the hippocampus, while BER exerted no significant effects on vesicular monoamine transporter mRNA expression in the hippocampus of rats with PTSD. These results suggest that BER had anxiolytic-like effects on behavioral and biochemical measures associated with anxiety. These findings support a role for reduced anxiety altered DAergic transmission and reduced anxiety in rats with PTSD. Thus, BER may be a useful agent to treat or alleviate psychiatric disorders like those observed in patients with PTSD.

초발 주요우울장애 환자의 우울 삽화 및 관해 상태에서 신경인지기능 결함 비교 (Comparison of Neuropsychological Deficits between Depressed Episode and Remission in First-onset Patients with Major Depressive Disorder)

  • 허지원;김용구
    • 생물정신의학
    • /
    • 제15권2호
    • /
    • pp.92-100
    • /
    • 2008
  • Objectives : The purpose of this study was to investigate 1) the neuropsychological deficits with major depressive disorder(MDD) in depressed state and 2) the changes of neuropsychological dysfunctions during depressed episodes and remitted periods in the MDD group. Methods : 12 patients with MDD and 70 normal controls who were diagnosed and classified by DSM-IV and SCID-IV interview participated in this study. The psychopathology was measured using the Hamilton rating scale for depression(HAM-D) and Brief Psychiatric Rating Scale(BPRS). The memory function, executive function, and sustained attention were measured by a trained psychologist using the Korean version of Memory Assessment Scale(K-MAS), Wisconsin Card Sorting Test(WCST), and Vigilance(VIG) and Cognitrone (COG) in Vienna Test System. After 6 weeks of treatment, we retested the cognitive tests in order to measure the cognitive functions in remitted states. Results : Patients with MDD achieved significantly lower score in sentence immediately recall, verbal memory score and total memory score of the K-MAS, total errors of the WCST, response time of Vigilance and response time at "Yes" response of Cognitrone than normal controls at baseline. After 6 weeks of medication, the psychiatric symptoms in the patient group were attenuated, and most of the neuropsychological functions including attention, memory, and frontal/executive function were improved except for response time of Cognitrone. Conclusions : This study provides evidence for distinct neuropsychological deficits in patients with MDD on their depressed states and remitted periods. The impairment on response time remains after remission, and this would be a trait marker of major depressive disorder.

  • PDF